User seeks participants for Verteporfin group buy. Verteporfin, FDA approved, may regenerate hairfollicles and sweat glands through heavy microneedling.
Finasteride and minoxidil can cause significant initial hair shedding, but regrowth typically follows after a few months. Shedding is not a regular occurrence but may happen to strengthen hairfollicles.
The user experienced hair regrowth after using oral minoxidil, topical minoxidil, dutasteride, multivitamins, and ketoconazole shampoo, with noticeable improvement in the hairline after 11 months. They reported a burning sensation on the scalp and questioned if single hairfollicles could become multi-hairfollicles.
Diffuse thinners often experience more hair regrowth with DHT blockers like finasteride, possibly due to less DHT sensitivity and the presence of miniaturized, not completely bald, follicles. However, regrowth varies widely among individuals, influenced by factors like genetics, the stage of hair loss, and treatment methods such as minoxidil, microneedling, and dermarolling.
A user is starting a hair loss treatment with a 3-in-1 spray containing finasteride, minoxidil, and tretinoin. They are concerned about whether to continue shaving their head and how to determine if hairfollicles are dead.
The user is experiencing new hair growth after using oral dutasteride, topical minoxidil, and microneedling, but is concerned about black dots on the hairline, which might be clogged pores or dormant follicles. The user previously used a topical minoxidil/finasteride spray and had good results, despite a shedding phase after switching treatments.
Liposomal formulations of finasteride and minoxidil may enhance drug delivery to the skin and hairfollicles more effectively than traditional solutions, potentially improving treatment outcomes. However, more human clinical trials are needed to confirm these benefits.
Verteporfin is being explored for its potential to improve hair transplant outcomes by reducing scarring and increasing donor hairfollicles. There is skepticism about the results, with some claiming misleading presentation of evidence.
The user discusses their hair loss experience, exploring various hypotheses including thyroid levels, vitamin D, DHEA, nutritional deficiency, diabetes, seborrheic dermatitis, lack of nutrition to hairfollicles, chronic inflammation, female pattern hair loss causes, cortisol, and prolactin levels. They are currently using finasteride, beta-sitosterol, and have tried topical dutasteride and microneedling therapy.
The conversation discusses starting Minoxidil for hair loss and suggests also using finasteride to prevent further balding. Minoxidil is expected to thicken current hair, but won't stop hairfollicles from dying.
User "Ant1pal" shares progress pictures of hair regrowth using Minoxidil, Estradiol valerate, and Spironolactone. Users discuss potential side effects and the possibility of localizing estrogen to hairfollicles for better treatment.
The user is using RU58841 for hair regrowth on the temples and is considering adding minoxidil. They are questioning the potential for vellus hairs to develop into fuller hair and the possibility of reactivating dormant follicles.
Delayed release oral minoxidil is seen as a promising advancement for hair loss treatment, offering safer, higher doses and more consistent hairfollicle stimulation compared to current options. However, it is not expected to replace finasteride or dutasteride, as it does not prevent androgenetic alopecia.
Verteporfin is discussed as a potential treatment for hair regrowth, but skepticism exists about its effectiveness in regenerating extracted hairfollicles. The conversation also mentions the possibility of needing a hair transplant by 2028.
PP-405, a potential hair loss treatment, shows promise in stimulating dormant hairfollicles and may help with various hair loss types. Current treatments like Minoxidil are still recommended as PP-405 is in early trials and may take years to become available.
The conversation is about future hair loss treatments. Current treatments mentioned include finasteride, minoxidil, and RU58841, with potential future treatments like GT20029, TDM-105795, JW0061, and follicle cloning.
The post discusses the theory that persistent dandruff in areas prone to hair loss could be a sign of hairfollicles dying due to DHT, indicating balding. The responses vary, with some users noting improvements in dandruff and hair loss with treatments like Dutasteride, while others experienced hair loss without dandruff.
He Shou Wu (Fo Ti) extract was found to prolong the hair growth phase, inhibit 5-alpha-reductase (like finasteride), reduce androgen receptors, and increase growth factors, potentially outperforming minoxidil in recovering hairfollicle size after DHT exposure. Two compounds, emodin and TSG, are identified as responsible for these effects and warrant further investigation.
CosmeRNA, a new hair loss treatment, is expected to release soon and may become part of the "big three" treatments alongside finasteride and minoxidil. It works differently from finasteride by targeting androgen receptors in hairfollicles, potentially offering fewer side effects.
A 26-year-old male is still experiencing hair loss after a year of using Dutasteride and is considering using CB0301 (Breezula) to block all androgens on his follicles. He is looking for a reliable source to purchase CB0301 and inquires about the availability of a premade solution.
A 24-year-old woman with thinning hair is using Minoxidil, saw palmetto, biotin, rosemary oil, and ketoconazole. She seeks advice on whether to try finasteride or dutasteride, the effects of Minoxidil shedding, and the significance of her hairfollicle condition.
Breezula shows promising results for hair loss, with one trial showing a 539% improvement and another 168%, but lacks combination data with treatments like minoxidil or dutasteride. Its mechanism differs from finasteride, potentially offering fewer side effects by blocking receptors locally at the follicle.
A South Korean company, Therazyne, has developed a promising hair loss treatment using a WNT chain surrogate that binds to Frizzled 7, with human follicle testing expected soon. Current treatments like minoxidil and finasteride are not seen as cures, and while optimism exists for future solutions like PP405, approval processes are lengthy.
The user started using a hair loss treatment regimen including 5% minoxidil spray twice daily, 1% finasteride spray once daily, microneedling weekly, and ketoconazole shampoo twice a week, experiencing significant hair shedding. The shedding is seen as a positive sign, indicating hairfollicles are entering a new growth phase.
An 18-year-old with diffuse hair thinning is considering switching from a topical Minoxidil 10% + Finasteride 0.1% solution to Minoxidil 5% foam and oral Finasteride 0.5mg, while also addressing vitamin D deficiency and potential scalp inflammation. Users suggest using Nizoral shampoo for inflammation, considering dutasteride for better results, and maintaining vitamin D levels to protect hairfollicles from DHT.
A 31-year-old male experiencing hair thinning since age 25-26 uses minoxidil, finasteride, a red laser cap, and microneedling to promote hair growth. Users suggest reducing microneedling frequency to once a week to avoid damaging hairfollicles.
Some individuals do not respond to oral minoxidil for hair loss, despite it generally working by improving blood flow to hairfollicles. Factors like metabolism, drug interactions, and individual variations in the drug's activation may influence its effectiveness.
The conversation discusses the use of Verteporfin in hair loss treatment. It suggests that Verteporfin could potentially regenerate hairfollicles instead of forming scars, providing an unlimited donor supply for hair transplants.